Alzheimer's Disease Neuroimaging Initiative
The Alzheimer's Disease Neuroimaging Initiative (ADNI) was launched in 2004 to explore combinations of biomarkers (currently existing neuroimaging, cerebrospinal fluid, and blood markers) to determine which are most powerful for diagnosis of Alzheimer's disease and monitoring of treatment effects. Its overall goals are:
- Development of optimized methods and uniform standards for the acquisition of longitudinal, multicenter MRI and FDG-PET data on patients with Alzheimer's disease and mild cognitive impairment as well as healthy elderly controls;
- Implementation of these optimized methods and acquisition of longitudinal structural and metabolic imaging data in a large cohort of healthy elderly, mildly cognitively impaired, and Alzheimer's disease patients and validation of these imaging surrogates with parallel acquired biomarkers and clinical and cognitive measures;
- Identification of those neuroimaging measures, cognitive measures, and biomarkers, which provide the maximum power for the diagnosis of mild cognitive impairment, and Alzheimer's disease and for the assessment of treatment effects in trials involving healthy elderly, mildly cognitively impaired, and Alzheimer's disease;
- Creation of a generally accessible imaging and clinical data repository, which describe longitudinal changes in brain structure and metabolism, cognitive function, and biomarkers in healthy elderly, mildly cognitively impaired, and Alzheimer's disease patients.
Overview
- Acronym
- ADNI
- Website
- ADNI
- Investigators
-
- Contacts
-
General Design
- Study design
- Case-control
- Start - End Year
- 2004 - 2016
- General Information on Follow Up (profile, frequency)
-
ADNI1:
- Alzheimer's disease subjects are studied at 0, 6, 12, and 24 months with a clinical exam. At month 18, phone contact is made.
- Mild cognitive impairment subjects with high risk for conversion to Alzheimer's disease are studied at 0, 6, 12, 18, 24, and 36 months. At month 30, phone contact is made.
- Age matched controls are studied at 0, 6, 12, 24 and 36 months with a clinical exam. At months 18 and 30, phone contact is made.
ADNI GO:
- Early mild cognitive impairment subjects are followed up at 0, 3, 6, 12, and 18 months
- Cognitively normal and late mild cognitive impairment subjects have four scheduled visits, two in-clinic, and two telephone checks
ADNI2:
- Cognitively normal and early/late mild cognitive impairment subjects are followed up at 0, 3, and 6 months, with ongoing annual clinic visits, and ongoing 6 month interim phone calls
- New Alzheimer's disease participants are followed at 0, 3, 6, 12, 18, and 24 months, with ongoing 6 month follow-ups by phone
- Recruitment Target
-
- Individuals
- Number of Participants
- 1,650
- Number of Participants with Biological Samples
- 1,650
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Marker Paper
Weiner MW et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7.
PUBMED 23932184Supplementary Information
For additional information, access to data and study documentation, please go to http://adni.loni.usc.edu/.
Timeline
Populations
The normal control participants are aged 55 to 90 years, matched for age to MCI and AD participants, and recruited across Canada and the United States.
Selection Criteria
- Minimum age
-
55
- Maximum age
-
90
- Countries
-
- Canada
- United States of America
- Canadian Provinces
-
- British Columbia
- Ontario
- Quebec
- Territory
-
Participants were enrolled in 50 sites across the US and Canada.
- Other Criteria
-
A study partner must be available for each participant to provide an independent evaluation of functioning. All participants must be able to speak English or Spanish and be willing and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up. Specific psychoactive medicines were excluded.
The normal control participants had to have a MMSE score between 24-30, a clinical dementia rating of 0, being non-depressed, non-mildly cognitively impaired, and non-demented.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 229
- Number of Participants with Biological Samples
- 229
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ADNI1 - Normal Controls |
|
|
2004 | 2009 |
| 1 | ADNI GO - Follow-up from ADNI1 |
|
|
2009 | 2011 |
| 2 | ADNI2 - Follow-up from ADNI1/GO |
|
|
2011 | 2016 |
The participants with mild Alzheimer's disease are aged 55 to 90 years and recruited across Canada and the United States.
Selection Criteria
- Minimum age
-
55
- Maximum age
-
90
- Countries
-
- Canada
- United States of America
- Canadian Provinces
-
- British Columbia
- Ontario
- Quebec
- Territory
-
Participants were enrolled in 50 sites across the US and Canada.
- Other Criteria
-
A study partner must be available for each participant to provide an independent evaluation of functioning. All participants must be able to speak English or Spanish and be willing and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up. Specific psychoactive medicines were excluded.
Mild Alzheimer's diseased participants had to have a MMSE score between 20 and 26, a clinical dementia rating of 0.5 or 1.0, and meet NINCDS/ADRDA criteria for probably Alzheimer's disease.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 192
- Number of Participants with Biological Samples
- 192
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ADNI1 - Mild AD |
|
|
2004 | 2009 |
The mildly cognitively impaired participants are aged 55 to 90 years and recruited across Canada and the United States.
Selection Criteria
- Minimum age
-
55
- Maximum age
-
90
- Countries
-
- Canada
- United States of America
- Canadian Provinces
-
- British Columbia
- Ontario
- Quebec
- Territory
-
Participants were enrolled in 50 sites across the US and Canada.
- Other Criteria
-
A study partner must be available for each participant to provide an independent evaluation of functioning. All participants must be able to speak English or Spanish and be willing and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up. Specific psychoactive medicines were excluded.
Mildly cognitively impaired subjects had to have a MMSE score between 24 and 30, a memory complaint, have objective memory loss measured by education adjusted scored on Wechsler Memory Scale Logical Memory II, a clinical dementia rating of 0.5, absence of significant levels of impairment in other cognitive domains, essentially preserved activities of daily living, and an absence of dementia.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 398
- Number of Participants with Biological Samples
- 398
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ADNI1 - MCI |
|
|
2004 | 2009 |
| 1 | ADNI GO - Follow-up from ADNI1 |
|
|
2009 | 2011 |
| 2 | ADNI2 - Follow-up from ADNI1/GO |
|
|
2011 | 2016 |
The early mildly cognitively impaired participants are aged 55 to 90 years and recruited across Canada and the United States.
Selection Criteria
- Minimum age
-
55
- Maximum age
-
90
- Countries
-
- Canada
- United States of America
- Canadian Provinces
-
- British Columbia
- Ontario
- Quebec
- Territory
-
Participants were enrolled in 50 sites across the US and Canada.
- Other Criteria
-
A study partner must be available for each participant to provide an independent evaluation of functioning. All participants must be able to speak English or Spanish and be willing and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up. They also had to be willing to undergo at least one lumbar puncture at baseline. Specific psychoactive medicines were excluded.
Early mildly cognitively impaired participants had to have a MMSE score between 24 and 30, a memory complaint (reported by subject or informant), objective memory loss measured by education adjusted scored on delayed recall of one paragraph from Wechsler Memory Scale Logical Memory II, a clinical dementia rating of 0.5, absence of significant levels of impairment in other cognitive domains, essentially preserved activities of daily living, and an absence of dementia.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 200
- Number of Participants with Biological Samples
- 200
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ADNI GO - EMCI |
|
|
2009 | 2011 |
| 1 | ADNI2 - Follow-up from ADNI1/GO |
|
|
2011 | 2016 |
The participants with mild Alzheimer's disease are aged 55 to 90 years and recruited across Canada and the United States.
Selection Criteria
- Minimum age
-
55
- Maximum age
-
90
- Countries
-
- Canada
- United States of America
- Canadian Provinces
-
- British Columbia
- Ontario
- Quebec
- Territory
-
Participants were enrolled in 50 sites across the US and Canada.
- Other Criteria
-
A study partner must be available for each participant to provide an independent evaluation of functioning. All participants must be able to speak English or Spanish and be willing and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up. Specific psychoactive medicines were excluded.
Mild Alzheimer's diseased participants had to have a MMSE score between 20 and 26, a clinical dementia rating of 0.5 or 1.0, and meet NINCDS/ADRDA criteria for probably Alzheimer's disease.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 200
- Number of Participants with Biological Samples
- 200
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ADNI2 - Mild AD |
|
|
2011 | 2016 |
The early mildly cognitively impaired participants are aged 55 to 90 years and recruited across Canada and the United States.
Selection Criteria
- Minimum age
-
55
- Maximum age
-
90
- Countries
-
- Canada
- United States of America
- Canadian Provinces
-
- British Columbia
- Ontario
- Quebec
- Territory
-
Participants were enrolled in 50 sites across the US and Canada.
- Other Criteria
-
A study partner must be available for each participant to provide an independent evaluation of functioning. All participants must be able to speak English or Spanish and be willing and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up. They also had to be willing to undergo at least one lumbar puncture at baseline. Specific psychoactive medicines were excluded.
Early mildly cognitively impaired participants had to have a MMSE score between 24 and 30, a memory complaint (reported by subject or informant), objective memory loss measured by education adjusted scored on delayed recall of one paragraph from Wechsler Memory Scale Logical Memory II, a clinical dementia rating of 0.5, absence of significant levels of impairment in other cognitive domains, essentially preserved activities of daily living, and an absence of dementia.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 150
- Number of Participants with Biological Samples
- 150
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ADNI2 - EMCI |
|
|
2011 | 2016 |
The mildly cognitively impaired participants are aged 55 to 90 years and recruited across Canada and the United States.
Selection Criteria
- Minimum age
-
55
- Maximum age
-
90
- Countries
-
- Canada
- United States of America
- Canadian Provinces
-
- British Columbia
- Ontario
- Quebec
- Territory
-
Participants were enrolled in 50 sites across the US and Canada.
- Other Criteria
-
A study partner must be available for each participant to provide an independent evaluation of functioning. All participants must be able to speak English or Spanish and be willing and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up. Specific psychoactive medicines were excluded.
Mildly cognitively impaired subjects had to have a MMSE score between 24 and 30, a memory complaint, have objective memory loss measured by education adjusted scored on Wechsler Memory Scale Logical Memory II, a clinical dementia rating of 0.5, absence of significant levels of impairment in other cognitive domains, essentially preserved activities of daily living, and an absence of dementia.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 150
- Number of Participants with Biological Samples
- 150
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ADNI2 - LMCI |
|
|
2011 | 2016 |
The normal control participants are aged 55 to 90 years, matched for age to MCI and AD participants, and recruited across Canada and the United States.
Selection Criteria
- Minimum age
-
55
- Maximum age
-
90
- Countries
-
- Canada
- United States of America
- Canadian Provinces
-
- British Columbia
- Ontario
- Quebec
- Territory
-
Participants were enrolled in 50 sites across the US and Canada.
- Other Criteria
-
A study partner must be available for each participant to provide an independent evaluation of functioning. All participants must be able to speak English or Spanish and be willing and able to undergo all test procedures including neuroimaging, and agree to longitudinal follow up. Specific psychoactive medicines were excluded.
The normal control participants had to have a MMSE score between 24-30, a clinical dementia rating of 0, being non-depressed, non-mildly cognitively impaired, and non-demented.
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 150
- Number of Participants with Biological Samples
- 150
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | ADNI2 - Normal Controls |
|
|
2011 | 2016 |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
Areas of Information Collected per per Population and Data Collection Event
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|